- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- EGFR positive
- PD-L1 negative
- PR positive
- EGFR negative
- KRAS positive
- ALK negative
- ER negative
- BRAF positive
- PR negative
- CD20 positive
- ALK positive
- BRCA1 positive
- BRAF negative
- HLA-A positive
- BRCA2 positive
- HLA positive
- p16 positive
- CD19 positive
- ROS1 negative
- MET positive
- IDH positive
- PIK3CA positive
- ROS1 positive
- MYC positive
- RET positive
- p16 negative
- MSI-H positive
- dMMR positive
- HR positive
- IDH negative
- TP53 positive
- BCL2 positive
- NRAS positive
- HLA negative
- MSS positive
- RET negative
- BCL6 positive
- HPV negative
- MET negative
- NF1 positive
- HLA-A negative
- KRAS negative
- PALB2 positive
- RB1 positive
- ctDNA positive
- ANA positive
- BRCA positive
- CFTR positive
- HPV positive
- RAS negative
- RAS positive
- TP53 negative
- BCR-ABL1 positive
- BRCA1 negative
- CCND1 positive
- Ex19del positive
- L858R positive
- MSI-H negative
- NTRK positive
- RB1 negative
- dMMR negative
- BRCA2 negative
- CD5 positive
- CLDN18.2 positive
- FGFR2 positive
- FLT3 positive
- HBsAg positive
- MMR negative
- NTRK negative
- PTEN positive
- anti-dsDNA positive
- pMMR positive
- ATM positive
- COL7A1 positive
- FGFR3 positive
- HRAS positive
- KIT positive
- MGMT negative
- MLH1 positive
- MMR positive
- MSH2 positive
- MSH6 positive
- PMS2 positive
- T790M positive
- TTR positive
- t(11;14) positive
- ABCA4 positive
- CD123 positive
- CD19 negative
- CD22 positive
- DLL3 positive
- EPCAM positive
- GPC3 positive
- HbSS positive
- MDM2 positive
- NPM1 positive
- NRAS negative
- SMN1 positive
- TROP2 negative
- TROP2 positive
- ZnT8 positive
- p53 positive
- APC positive
- APOL1 positive
- APP positive
- BRCA negative
- C5 positive
- CCNE1 positive
- CD23 positive
- CD33 positive
- DMD positive
- EBV positive
- ER or PR positive
- FLT3 negative
- FMR1 positive
- G719X positive
- HPV16 positive
- IA-2 positive
- JAK2 positive
- KMT2A positive
- Ki-67 positive
- L861Q positive
- MGMT positive
- MSI negative
- MSI positive
- MSS negative
- MTAP positive
- MYC negative
- NF2 positive
- PDGFRA positive
- PSEN1 positive
- PSEN2 positive
- Philadelphia chromosome negative
- Philadelphia chromosome positive
- PiZZ positive
- RF positive
- RHO positive
- S768I positive
- STK11 positive
- TET2 positive
- TMB positive
- UGT1A1 positive
- anti-MuSK positive
- β-thalassemia positive
- 11q negative
- 11q positive
- ABCD1 positive
- AFP positive
- AGXT positive
- AKT negative
- AKT1 positive
- ALPL positive
- AR positive
- ARID1A positive
- ASXL1 positive
- Anti-Smith positive
- Aβ1-42 positive
- CCND1 negative
- CD20 negative
- CD30 positive
- CD8 positive
- CDK4 positive
- CEACAM5 positive
- CLDN6 positive
- COL1A1 positive
- COL1A2 positive
- DNMT3A positive
- Del(17p) negative
- EBV DNA positive
- ENPP1 positive
- ER/PR positive
- FGFR positive
- FOXO1 fusion negative
- FRα positive
- FVIII positive
- GBA positive
- GLA positive
- GREM1 positive
- GRN positive
- HA-1 positive
- HBB mutation positive
- HBB positive
- HBV DNA negative
- HBeAg positive
- HEXA positive
- HEXB positive
- HR negative
- HRD negative
- HRD positive
- HTT positive
- HbE positive
- HbSC positive
- IAA positive
- IDS positive
- IGHV negative
- IgHV positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1 or more Spontaneous Breathing Trials (SBTs)
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Allogeneic Hematopoietic Cell Transplantation
- Anti-CTLA4 Therapy
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
8636 trials
Trials Without a Placebo
1
2
3
…50